CAR-T therapy: Trailblazing CAR(ing) in cancer treatment (IMAGE)
Caption
Figure 2: Challenges and emerging advancements in CAR-T therapy. The schematic representation outlines the major limitations associated with CAR-T treatment, including various toxicities, limited efficacy in solid tumors, on-target/off-tumor effects, hypogammaglobulinemia, time constraints and associated costs. The challenges could be substantially addressed with key advancements such as next-generation CAR constructs, optimized supportive care including tocilizumab and corticosteroids, and the development of allogeneic or alternative CAR-T platforms. Enhanced clinical management strategies such as prophylactic measures and the use of specialized treatment centres could further contribute to improving safety, feasibility, and overall therapeutic outcomes.
Credit
Copyright: © 2026 Saqib et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Usage Restrictions
With credit to the original source.
License
Original content